The US Drug Enforcement Administration has proposed new rules that mean, for the first time, medications containing delta-9 THC from the cannabis plant could be eligible for approval by the US Food and Drug Administration (FDA). The rules, if enacted, would move the cannabis plant from a schedule I to a schedule III substance, so its federal legal status would shift drastically from a narcotic with “no accepted medical use” to a regulated medication.
Nearly 4 million Americans are already using medical cannabis in states where it’s been legalized, contradicting federal laws. Given that so many Americans already have access to some form of medical cannabis, it’s unclear whether pharmaceutical companies would benefit from seeking FDA approval for cannabis-based drugs.
